Welcome to Bristol Myers Squibb California

Mark Rolfe, Ph.D., leads an early drug discovery team focused on targeted protein degradation – removing disease-causing proteins from cells by leveraging the body’s natural system of maintaining balanced protein levels.

Chetana Rao, Ph.D., leads site and strategy operations at Bristol Myers Squibb’s Redwood City and San Francisco sites, as well as diversity and inclusion initiatives for the company in the Bay area. 

Miranda Broz, Ph.D., serves on a team responsible for exploring parts of the tumor microenvironment (TME) to better uncover how a tumor functions, with the hope of eventually turning these findings into novel treatment options that will benefit patients with difficult-to-treat cancers. 

Bristol Myers Squibb is driven to understand human biology and the complexities of cancer in order to advance the next generation of cancer therapies.

Bristol Myers Squibb is pursuing a multitude of diverse approaches in cell therapy to attack disease from new perspectives. 

Hear from Mark Rolfe, Ph.D., as he describes protein homeostasis and protein degradation, and how the company is leveraging this novel research to make a difference for patients.

As a scientific research community, our work is never done for cancer patients. Building upon established science allows researchers to pursue new approaches, test new hypotheses and – ultimately – uncover new answers to emerging and enduring questions that may address unmet needs for patients. 

Ho Cho, Ph.D., discusses how it’s never too late to change how we think about failure, and when we make that change, we open the door to developing ourselves in new and powerful ways.

People and Business Resource Groups (PBRGs) represent one key strategy we use to support the business objectives, career advancement and development needs of our employees.

Learn more about our impact in California.

Science and technology are at the core of everything we do. We're always eager to open young minds to the exciting possibilities of both. 

University of California San Francisco will create an in-person and virtual-based patient navigation program to enhance the quality of cancer care for English, Chinese, and Vietnamese patients newly diagnosed with colorectal, liver, or lung cancer in the Greater San Francisco Bay Area.

The CFCCC will build a formal collaborative network as a hub/spoke model between community organizations, CalOptima primary and specialty care providers, and UCI’s specialists to provide more efficient and effective cancer care for low income MediCal Vietnamese, Korean, and Chinese patients in Orange County, California. 

University of California Davis, in a collaborative partnership with the Health and Life Organization, will prospectively identify and follow Asian American patients across the cancer continuum to improve cancer prevention and control behaviors to create a New Patient Referral service between a federally qualified healthcare center lookalike and National Cancer Institute Comprehensive Cancer Center.

Learn about the science behind protein degradation and ongoing research that harnesses the power of this natural process.

Exploring the tumor microenvironment (TME) to better understand how cancer and the immune system coexist is a core component of Bristol Myers Squibb’s research and early development strategy.

Novel cell-based therapies that use a person’s own cells are unlocking new potential in the fight against some of the most difficult-to-treat cancers.